Facial Pyoderma Gangrenosum – Presentation of Two Clinical Cases and Literature Review

Małgorzata N. Grabarczyk; Kamila Zawadzińska-Halat; Jolanta Smyk; Maciej Pastuszczak

doi:10.5114/dr.2024.150242

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

6/2024
vol. 111

Send email

Copy url:

abstract:

Review article

Facial Pyoderma Gangrenosum – Presentation of Two Clinical Cases and Literature Review

Małgorzata N. Grabarczyk

¹

,

Kamila Zawadzińska-Halat

^{1, 2}

,

Jolanta Smyk

¹

,

Maciej Pastuszczak

^{1, 2}

Department of Internal Medicine, Dermatology and Allergology, the Specialist Hospital, Zabrze, Poland
Department of Dermatology in Zabrze, Silesian Medical University in Katowice, Poland

Dermatol Rev/Przegl Dermatol 2024, 111, 429-434

DOI: https://doi.org/10.5114/dr.2024.150242

Online publish date: 2025/05/21

View full text Get citation

PlumX metrics:

Pyoderma gangrenosum is a rare neutrophilic dermatosis characterized by a distinct clinical course and typical morphology of skin lesions. Most commonly, it affects the lower legs, while head and neck involvement is extremely rare. We present 2 cases of pyoderma gangrenosum manifesting on the face, with simultaneous exacerbation of inflammatory bowel disease. In the treatment regimen, anti-TNF-a inhibitors were administered alongside steroid therapy, leading to rapid remission of the skin lesions. Treatment with infliximab was associated with rapid remission of pyoderma gangrenosum and a reduction in the severity of the inflammatory process in the gastrointestinal tract. Infliximab is a highly effective option for managing facial pyoderma gangrenosum in patients with coexisting inflammatory bowel disease and should be considered as the first-line treatment. In the differential diagnosis of non-healing facial ulcers, pyoderma gangrenosum should be considered alongside neoplasms and granulomatosis with polyangiitis, particularly when the patient’s medical history suggests bowel disease.

keywords:

pyoderma gangrenosum, inflammatory bowel disease, tumor necrosis factor-a

Indeks osobowy

Facial Pyoderma Gangrenosum – Presentation of Two Clinical Cases and Literature Review

Małgorzata N. Grabarczyk 1 , Kamila Zawadzińska-Halat 1, 2 , Jolanta Smyk 1 , Maciej Pastuszczak 1, 2

pyoderma gangrenosum, inflammatory bowel disease, tumor necrosis factor-a

Małgorzata N. Grabarczyk

¹

,

Kamila Zawadzińska-Halat

^{1, 2}

,

Jolanta Smyk

¹

,

Maciej Pastuszczak

^{1, 2}